• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Charles River Labs to Acquire WuXi PharmaTech for $1.6B

Charles River Labs to Acquire WuXi PharmaTech for $1.6B

April 26, 2010
CenterWatch Staff

Preclinical contract research organization (CRO) Charles River Laboratories announced this morning plans to acquire Chinese CRO Wuxi PharmaTech in a deal valued at $1.6 billion.

The combined company will retain the Charles River name and continue to be led by Charles River president and CEO James Foster. WuXi CEO Dr. Ge Li will become corporate executive vice president and president of global discovery and China services, a new segment of the company. The acquisition will be finalized in the fourth quarter 2010.

Charles River also released its first quarter 2010 financial results this morning. Net sales for the quarter were $297.3 million, a decline of 1.4% from the same period last year. Net income for the quarter was $17.4 million, or $0.26 per diluted share, compared with net income of $25.4 million, or $0.38 per diluted share, for the first quarter 2009.

WuXi reported revenues of $270 million in 2009. 

Charles River is calling the WuXi deal a “transformational transaction,” which will enable the CRO to expand into China and expand its service offerings to include drug development services from molecule creation to first-in-human testing.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing